Kak M. Rebamipide in gastric mucosal protection and healing: An Asian perspective. World J Gastrointest Pharmacol Ther 2025; 16(1): 101753 [DOI: 10.4292/wjgpt.v16.i1.101753]
Corresponding Author of This Article
Manish Kak, DNB, FACG, MBBS, MD, MNAMS, Doctor, Department of Gastroenterology, Manipal Hospital, NH-24 Hapur Road, Near Landcraft Golflinks, Pandav Nagar, Ghaziabad 201002, Uttar Pradesh, India. manishkak@yahoo.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Pharmacol Ther. Mar 5, 2025; 16(1): 101753 Published online Mar 5, 2025. doi: 10.4292/wjgpt.v16.i1.101753
Rebamipide in gastric mucosal protection and healing: An Asian perspective
Manish Kak
Manish Kak, Department of Gastroenterology, Manipal Hospital, Ghaziabad 201002, Uttar Pradesh, India
Author contributions: Kak M contributed to conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, project administration, resources, software, supervision, validation, visualization and writing review and editing; the author has approved the final version of the article to be published.
Supported by Dr Reddy's Laboratories, Hyderabad, India.
Conflict-of-interest statement: The author declares no conflict of interest in publishing the manuscript.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Manish Kak, DNB, FACG, MBBS, MD, MNAMS, Doctor, Department of Gastroenterology, Manipal Hospital, NH-24 Hapur Road, Near Landcraft Golflinks, Pandav Nagar, Ghaziabad 201002, Uttar Pradesh, India. manishkak@yahoo.com
Received: September 26, 2024 Revised: December 5, 2024 Accepted: January 2, 2025 Published online: March 5, 2025 Processing time: 158 Days and 0.1 Hours
Abstract
This review emphasizes the exemplary safety and efficacy of rebamipide in the treatment of gastric ulcers and other mucosa-related disorders, positioning it as a viable candidate for inclusion in treatment guidelines across India and globally. An in-depth literature review of rebamipide was carried out on PubMed and Google Scholar. Rebamipide has a multifaceted mechanism of action, including prostaglandin synthesis, scavenging free radicals, and enhancing mucin production, leading to enhanced mucosal protection and ulcer healing. Rebamipide serves as a highly effective and safe treatment option for gastric ulcers and gastroesophageal reflux disease. The efficacy of this drug in treating ulcers often surpasses that of routinely used agents such as pantoprazole, sucralfate, misoprostol, famotidine, lansoprazole, and esomeprazole. This superiority of rebamipide can be attributed to the low rate of adverse events associated with it and its mild side effects, contributing to its widespread adoption across Southeast Asia and Russia. This popularity extends to its application beyond gastrointestinal ailments. Notably, it has been successfully employed in the treatment of ophthalmological, oncological, and bone regeneration-related issues. Rebamipide's exemplary safety and efficacy in treating gastric ulcers and other mucosa-related disorders support its potential for inclusion in treatment guidelines, not only in India but also globally.
Core Tip: This review highlights rebamipide’s superior safety and efficacy in treating gastric ulcers and mucosal disorders, making it a strong candidate for inclusion in global treatment guidelines. An extensive literature review reveals its multifaceted mechanism of action, including prostaglandin synthesis, free radical scavenging, and mucin production enhancement, leading to enhanced mucosal protection and ulcer healing. Rebamipide often surpasses other common treatments like pantoprazole and esomeprazole due to its low adverse event rate and mild side effects. Its broad application extends to ophthalmology, oncology, and bone regeneration, further underscoring its therapeutic versatility.
